| Document |
Document Title |
|
WO/2023/072890A1 |
The present invention refers to a process for preparing sucrose octasulfate octakistriethylammonium salt (TASOS) powder, comprising the steps of combining a TASOS solution with a polar organic solvent(s) and triethylamine, thereby obtain...
|
|
WO/2023/025189A1 |
The present invention provides a non-animal chondroitin sulfate (CS) oligosaccharide and a preparation method therefor. The preparation method in the present invention comprises steps in which an one-step chemical method and an enzyme ca...
|
|
WO/2022/183254A1 |
The invention relates inter alia to methods of producing sulfated oligosaccharide derivatives and intermediates thereof. The sulfated oligosaccharide derivatives may be represented by the following formula (I) wherein: X and Y are any D-...
|
|
WO/2022/053576A1 |
The present invention relates to a new class of compounds based on a hexose featuring at least two 6-fluorides. The class is useful as inhibitors of 4,6-dehydratase enzymes. Such inhibitors are suitable for use as a medicament, for examp...
|
|
WO/2021/189153A1 |
The present invention provides for use of fenretinide, fenretinide analog or pharmaceutically acceptable salts for the preparation of medicaments useful for the treatment of SARS-coronavirus, ARDS and SARS-coronavirus associated pneumoni...
|
|
WO/2021/184128A1 |
Disclosed are methods of treating a coronavirus infection (e.g., a SARS-CoV-2 infection) using colchicine, and methods of treating Kawasaki Disease or Kawasaki Disease Shock Syndrome, e.g., by administering colchicine to a subject in nee...
|
|
WO/2021/142312A1 |
Novel compositions comprising heparinoid-related compounds, manufacturing and treatment methods, kits and dosage forms thereof, are provided.
|
|
WO/2021/122793A1 |
The present invention relates to disaccharide compounds and their use as enhancers of transmucosal drug uptake.
|
|
WO/2021/055933A1 |
The present disclosure relates to disaccharides with defined sulfation patterns, and oligosaccharide mimetics comprising the disaccharides as repeating units linked in a head to tail fashion. The present disclosure further relates to met...
|
|
WO/2021/015622A1 |
The current invention concerns methods for the synthesis of 6-azido-6-deoxy-2-N-acetyl-monosaccharide-nucleoside diphosphate, in particular 6-azido-6-deoxy-2-N-acetyl-D- galactosamine-nucleoside diphosphate or 6-azido-6-deoxy-2-N-acetyl-...
|
|
WO/2020/146523A1 |
Provided herein are compositions of trehalose phospholipids and uses thereof, e.g., compounds and compositions comprising 6,6'-diphosphatidyltrehalose (diPT) and analogs thereof with modifications of the diPT chemical scaffold, that bind...
|
|
WO/2020/038278A1 |
The present invention relates to a novel camptothecin derivative and an application thereof, a tumor cell growth inhibitor, a ternary complex and a method for improving solubility of the camptothecin derivative. The camptothecin derivati...
|
|
WO/2020/015612A1 |
A fucosylated chondroitin sulfate oligosaccharide having the structure as shown in J, and further disclosed is a method for preparing the fucosylated chondroitin sulfate oligosaccharide: using a chondroitin sulfate A salt as a raw materi...
|
|
WO/2019/126873A1 |
Heptose-1-monophosphate-7-derivatives are modifiable immunomodulators that can be used to prepare clinically active conjugate compounds. Such conjugate compounds are useful in modulating an immune response in a subject.
|
|
WO/2019/124363A1 |
The present invention provides a pentosan polysulfate having an uronic acid content of 7.0-15.0 mass% and an acetyl group content of 0-2.0 mass% or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate ther...
|
|
WO/2019/118486A1 |
The present disclosure provides monosaccharide phosphoramidate prodrugs of monosaccharide monophosphates. The present disclosure further provides methods of treating diseases of conditions such as congenital disorders of glycosylation co...
|
|
WO/2019/113646A1 |
A method of N- or O-sulfation of a compound is described whereby the use of a co-solvent system comprising a participating component and a non-participating component, during the sulfation reaction, allows for the non-participating compo...
|
|
WO/2019/113032A1 |
High surface area metal catalysts, and methods of making and using the same, are described.
|
|
WO/2018/205010A1 |
Phosphorylated heptose compounds are useful in modulating an immune response in a subject. Also, the compounds are useful as adjuvants.
|
|
WO/2018/205009A1 |
Processes for the preparation of phosphorylated heptose compounds are provided. Embodiments of the invention relate to the chemical synthesis of heptopyranose phosphate compounds. Also, embodiments of the invention relate to the use of c...
|
|
WO/2018/129647A1 |
A purified oligosaccharide compound having antithrombotic activity or a mixture of a homologous compound thereof and a pharmaceutically acceptable salt thereof, a preparation method for the mixture, a pharmaceutical composition containin...
|
|
WO/2018/067730A1 |
The present invention provides a method of treating sepsis in a subject, comprising administering to the subject an effective amount of a compound of the formula wherein R1 and R2 may be H, OH, protonated phosphate, a phosphate salt, a s...
|
|
WO/2018/035050A1 |
Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The heptasulfated disaccharides administered orally have comparable bioavailability to the intravenous administered dosage form.
|
|
WO/2017/154938A1 |
[Problem] The purpose of the present invention is to provide a method for uniformly and efficiently producing a sugar having a sulfate group and/or phosphate group in the molecule or a compound containing the sugar. [Solution] The presen...
|
|
WO/2017/071152A1 |
Provided are a phosphoryl mannose pentasaccharide as shown in formula (I) and derivatives of the phosphoryl mannose pentasaccharide as shown in formulas (II)-(XI), and a preparation method thereof. In the preparation method of this inven...
|
|
WO/2017/024255A1 |
The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutica...
|
|
WO/2017/002120A1 |
Compounds useful for selectively eliminating senescent cells, compositions comprising same and uses thereof in treating diseases and disorders in which selective elimination of senescent cells is beneficial are provided. The compounds ar...
|
|
WO/2016/069826A1 |
Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae vims infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula (IV): The compounds, compositions, and methods pro...
|
|
WO/2016/069825A1 |
Provided are methods of preparing compounds and pharmaceutical compositions for treating Filoviridae virus infections the compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola vir...
|
|
WO/2016/069827A1 |
Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula (I), wherein the position of the nucleoside sugar...
|
|
WO/2016/054745A1 |
Novel methods and uses for modulating immune responses are provided. The methods and uses involve the use of a TIFA activator such heptose-1,7- 5 bisphosphate or an analogue or derivative thereof. The methods may be used to activate, inh...
|
|
WO/2016/037720A1 |
The present invention relates to methods of producing sugar phosphates by enzymatic transphosphorylation, wherein the phosphoryl transfer from phosphate donor substrates to sugar substrates is catalyzed by an enzyme having alpha-glucose-...
|
|
WO/2016/013938A1 |
The present invention relates to a family of carbohydrate monosulphate fatty acid esters, which contain less than 10 mole % of carbohydrate polysulphate fatty acid esters, and to a method of preparation thereof. The monosulphate carbohyd...
|
|
WO/2016/004512A1 |
A synthetic charged glycolipid is described comprising a sulfated saccharide group covalently linked to the tree sn-1 hydroxyl group of the glycerol backbone of an archaeal core lipid via a beta linkage. The synthetic charged glycolipids...
|
|
WO/2015/081297A1 |
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...
|
|
WO/2015/056011A1 |
A process for the production of a glycoconjugate by N-glycosylation of a protein or peptide comprising the sequence D/E-X-N-X-S/T, wherein each X is the same or different and is any natural amino acid other than proline, wherein the proc...
|
|
WO/2015/040209A1 |
A molecule responding to formula (I)of the glycocluster type with galactose residues at their extremities. Simple and efficient methods for the preparation of these compounds. Medical use of compounds (I) as inhibitors of infections by P...
|
|
WO/2015/021415A1 |
Methods and computer systems are described herein for identifying small molecules that bind to selected RNA structural features (e.g., to RNA secondary structures). Also described are compounds and compositions that modulate RNA function...
|
|
WO/2014/013495A1 |
The present invention relates to amphiphilic aminoglycoside (AG) derivatives, especially derivatives of tobramycin, kanamycin A and paromomycin comprising hydrophobic side chains linked to the AG moiety by various linkers. These novel de...
|
|
WO/2013/152279A1 |
The present invention provides methods of synthesizing moenomycin analogs of Formula (I). The present invention also provides compositions comprising a compound of Formula (I) and kits for synthesizing compounds of Formula (I).
|
|
WO/2013/081028A1 |
The present invention relates to an amyloid β-binding material which contains sugar, or a sugar residue derived from the sugar. According to the amyloid β-binding material of the present invention, the sugar or the sugar residue specif...
|
|
WO/2013/071409A1 |
A novel lipoteichoic acid (LTA) was isolated from C. difficile, the structure of which is illustrated below wherein n is an interger between 1 and 20, R3 and R4 are independently selected from C 14:0, C 16:0, C 16: l, C 18:0 or C18: l fa...
|
|
WO/2013/006906A1 |
There is provided methods for the enrichment, isolation and/or modification of the dermatan sulphate (DS) derived from sources including hide processing waste streams. There is also provided uses of dermatan sulphate and/or low molecular...
|
|
WO/2012/172104A1 |
The invention concerns a pentasaccharide compound of formula (I) and the salts thereof. The invention also concerns a pharmaceutical composition comprising the synthetic pentasaccharide compound of formula (I) and its salts. The inventio...
|
|
WO/2012/160337A1 |
Compounds which interact with HlsTONES Compounds of Formula I : • 4"'-Sulfo-Fucose [alpha]1-3 (4"-sulfo)-Fucose [alpha]1-3 (4'-Sulfo-Fu- cose [alpha]1-4-Glucuronic acid [beta]1-0-Methyl or • 4" "-Sulfo-Fucose [alpha]1-3 (4"-sulfo)-Fu...
|
|
WO/2012/146914A1 |
Compounds which are trehalose-6-phosphate or trehalose-6-phosphonate precursors of formula (I) or agriculturally acceptable salts thereof are provided: (I) The compounds are useful in increasing starch production in plants.
|
|
WO/2012/129651A1 |
The invention provides compounds of formula (I) with substituents as specified in claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the com...
|
|
WO/2012/113404A1 |
The present invention relates to providing compounds of general formula (1) wherein A is glycosyl residue of a mono-, di- or oligosaccharide in protected form and R is selected from optionally substituted aryl or optionally substituted h...
|
|
WO/2012/103990A1 |
The present invention relates novel phosphorainidates of monosaccharides of formula (I), wherein R1 is a monosaccharide group selected from A and B: R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16 and X are as defined h...
|
|
WO/2012/077828A1 |
The purpose of the present invention is to provide a prophylactic or therapeutic agent for inflammatory diseases, which can inhibit the function of an inflammatory cytokine and therefore can exhibit an anti-inflammatory effect. The prese...
|
